CurrentEmblemHealthPolicy N/A

Unituxin (dinutuximab) Usage in Cancer Treatment Policy

Defines accepted indications, contraindications, exclusions, dosing limits, setting requirements, and supporting evidence for Unituxin (dinutuximab) use in cancer treatment (primarily high-risk neuroblastoma). Applies to medication requests processed by Evolent for EmblemHealth lines of business.

Policy Summary

PayerEmblemHealth

PolicyUnituxin (dinutuximab) Usage in Cancer Treatment Policy

Policy CodePolicy N/A

Change TypeRevised (template conversion and reference updates)

Effective DateJul 1, 2025

Next Review Date

Key ActionEvolent must process and authorize all medication requests; requests must be supported by FDA labeling, CMS compendia, NCCN/ASCO guidelines, or acceptable peer-reviewed literature per CMS Chapter 15.

SourceLink

POLICY UPDATE CHANGES

Converted to new Evolent guideline template; replaces UM ONC_1387 Unituxin (dinutuximab) and updated references.

1Primary Covered Indication (Neuroblastoma)

17.5 mg/m2Single Dose Limit

5Maximum Cycles

J9999HCPCS Code

Covered with criteria: Unituxin (dinutuximab) is covered for treatment of unresectable high-risk neuroblastoma when all policy criteria are met (see coverage criteria and exclusions). Effective date: 2025-07-01; Last review: 2025-07-01.

Thresholds and Quick Facts

Single dose limit17.5 mg/m2

Maximum duration5 cycles

Age for high-risk definition> 18 months

HCPCS CodeJ9999

Initial Therapy Criteria (Medically Necessary)

Neuroblastoma - Coverage Criteria (Medically Necessary)

Covered when ALL of the following are met:

ALL of the following

The member has unresectable high-risk neuroblastoma
High risk is defined as members who are older than 18 months of age and have disseminated disease, or localized disease with unfavorable markers such as MYCN amplification (see Attachment A)
Refer to Attachment A for Children's Oncology Group risk strata
The member is in a hospital/acute care setting to mitigate potential risks of serious infusion reactions, capillary leak syndrome, and hypotension
Unituxin (dinutuximab) may be used in combination with chemotherapy or 13-cis-retinoic acid (isotretinoin), with or without granulocyte-macrophage colony-stimulating factor (sargramostim)
Combination therapy allowed per policy

Continuation Therapy Criteria

Continuation Request Exemption

Continuation requests for a not-approvable medication shall be exempt provided ALL of the following are met:

ALL of the following

The member has not experienced disease progression on the requested medication
The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization
Additional medication(s) are not being added to the continuation request

Contraindications / Warnings

Contraindications / Warnings (must NOT be administered)

Any of the following contraindications/warnings

Anaphylaxis: History of anaphylaxis to dinutuximab or any component of the formulation
Must permanently discontinue for anaphylaxis
Severe infusion reactions (US Boxed Warning): infusion reactions occurred in 26% of patients; must prehydrate and premedicate including antihistamines; monitor during and for at least 4 hours after infusion; immediately interrupt for severe infusion reactions
Permanently discontinue for anaphylaxis
Serious neurotoxicity: severe neuropathic pain and peripheral neuropathy—administer IV opioid prior to, during, and for 2 hours following infusion; discontinue for severe unresponsive pain, severe sensory neuropathy, and moderate to severe peripheral motor neuropathy
Follow opioid premedication and stop rules per labeling

Exclusion Criteria (Not Covered)

Exclusion Criteria (Not covered)

ANY of the following

Progression or prior anti-GD2: Unituxin (dinutuximab) is being used after disease progression with the same regimen or prior anti-disialoganglioside (GD2) antibody therapy (e.g., Danyelza (naxitamab))
Single dose limit: Dosing exceeds single dose limit of Unituxin (dinutuximab) 17.5 mg/m217.5 mg/m2
Maximum cycles: Treatment exceeds the maximum duration limit of 5 cycles5 cycles
Investigational/off-label: Investigational use with an off-label indication that is not sufficient in evidence or not generally accepted by the medical community (insufficient if not supported by CMS-recognized compendia or acceptable peer-reviewed literature)
See policy for adequacy of evidence criteria (CMS compendia, peer-reviewed literature, clinically meaningful outcomes)

Provider Actions

Prior Authorization

Prior authorization requirement

Evolent is responsible for processing all medication requests. Medications not authorized by Evolent may be deemed not approvable and not reimbursable. Requests must be supported by FDA-approved product labeling, CMS-recognized compendia, NCCN/ASCO clinical guidelines, or acceptable peer‑reviewed literature per the CMS Medicare Benefit Policy Manual Chapter 15.

J9999

Documentation Required

Clinical documentation for indication and risk mitigation

Document that the member has unresectable high‑risk neuroblastoma, including age and extent of disease or presence of unfavorable markers (e.g., MYCN amplification). Document that treatment will occur in an inpatient/hospital setting to mitigate infusion and capillary leak risks, and specify the planned combination regimen (chemotherapy or isotretinoin ± sargramostim).

Example unfavorable marker: MYCN amplification

Denial Risk

Denial risk for prior anti-GD2 therapy or progression

Claims may be denied if Unituxin is requested after disease progression on the same regimen or after prior anti‑GD2 antibody therapy (for example, naxitamab).

J9999

Billing Rule

Dose and duration limits

Single dose limit for Unituxin is 17.5 mg/m2 and the maximum treatment duration is 5 cycles. Claims exceeding the single dose limit or the maximum of 5 cycles may be excluded from coverage.

J9999
Single dose limit: 17.5 mg/m2
Maximum duration: 5 cycles

Documentation Required

Safety monitoring and premedication documentation

Document required prehydration and premedication (including antihistamines), administration of IV opioid for neuropathic pain, and monitoring for infusion reactions during and for at least 4 hours after each infusion.

Clinical Evidence

Evidence: Phase III long-term follow-up — Yu AL et al. Clin Cancer Res. 2021; reports supporting use in high-risk neuroblastoma; Prescribing information — Unituxin prescribing information, United Therapeutics Corp. 2020; NCCN/Compendia — NCCN Cancer Guidelines and Drugs and Biologics Compendium 2025 cited as acceptable support.

Background

Background: Unituxin (dinutuximab) is an anti-GD2 monoclonal antibody indicated for high-risk neuroblastoma and carries significant risks including infusion reactions, capillary leak syndrome, hypotension, and neuropathic pain. Use must be supported by recognized compendia, guidelines, or peer-reviewed literature per CMS policy.

High-risk neuroblastoma

DefinitionMembers older than 18 months with disseminated disease, or localized disease with unfavorable markers such as MYCN amplification

Revision History

2024-07update

Updated NCH verbiage to Evolent

2025-07update

Converted to new Evolent guideline template; replaces UM ONC_1387 Unituxin (dinutuximab) and updated references

2025-07-01effective_dateLatest

Policy effective date